The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices

Maria A. Meier | Clement E. Lemercier | Christoph Kulisch | Béla Kiss | Balázs Lendvai | Nika Adham | Zoltan Gerevich

1Institute of Neurophysiology, Charité – Universitätsmedizin Berlin, Berlin, Germany
2Pharmacological and Drug Safety Research, Gedeon Richter Plc, Budapest, Hungary
3External Science and Innovation, Allergan Plc, Madison, New Jersey, USA

Background and Purpose: Gamma oscillations are fast rhythmic fluctuations of neuronal network activity ranging from 30 to 90 Hz that establish a precise temporal background for cognitive processes such as perception, sensory processing, learning, and memory. Alterations of gamma oscillations have been observed in schizophrenia and are suggested to play crucial roles in the generation of positive, negative, and cognitive symptoms of the disease.

Experimental Approach: In this study, we investigated the effects of the novel antipsychotic cariprazine, a D3-preferring dopamine D3/D2 receptor partial agonist, on cholinergically induced gamma oscillations in rat hippocampal slices from treatment-naïve and MK-801-treated rats, a model of acute first-episode schizophrenia.

Key Results: The D3 receptor-preferring agonist pramipexole effectively decreased the power of gamma oscillations, while the D3 receptor antagonist SB-277011 had no effect. In treatment-naïve animals, cariprazine did not modulate strong gamma oscillations but slightly improved the periodicity of non-saturated gamma activity. Cariprazine showed a clear partial agonistic profile at D3 receptors at the network level by potentiating the inhibitory effects when the D3 receptor tone was low and antagonizing the effects when the tone was high. In hippocampal slices of MK-801-treated rats, cariprazine allowed stabilization of the aberrant increase in gamma oscillation power and potentiated resynchronization of the oscillations.

Conclusion and Implications: Data from this study indicate that cariprazine stabilizes pathological hippocampal gamma oscillations, presumably by its partial agonistic profile. The results demonstrate in vitro gamma oscillations as predictive biomarkers to study the effects of antipsychotics preclinically at the network level.

1 INTRODUCTION

To date, schizophrenia is understood as a neurodevelopmental disease arising from complex interactions between genetic and environmental factors, inducing changes in neuronal networks and alterations in multiple neurotransmitter systems (Birnbaum & Weinberger, 2017). The pathophysiology underlying the symptoms of schizophrenia remains poorly understood. Some of the molecular changes ultimately leading to the symptoms of the disease have been partially uncovered by the beneficial effects of antipsychotics. These drugs are used primarily to decrease the positive symptoms of the disease, which are mainly...
attributed to an excessive dopaminergic tone leading to over-activation of dopamine D2-like receptors (Miyamoto, Miyake, Jarskog, Fleischhacker, & Lieberman, 2012). However, much less is known regarding the molecular and network backgrounds of negative and cognitive symptoms, as very few drugs with multiple receptor profiles have been associated with alleviation of these symptoms in the clinic.

**Cariprazine** (United States: Vraylar®; Europe: Reagila®) is a novel antipsychotic drug that was recently approved for the treatment of schizophrenia in adults (United States and Europe) and has shown treatment benefits against risperidone in patients with predominantly negative symptoms (Németh et al., 2017). Cariprazine is a high-affinity dopamine D3-preferring D3/D2 receptor partial agonist with additional partial agonistic action at 5-HT1A receptors. It also exhibits high affinity for the 5-HT2B and moderate affinity for the 5-HT2A receptors, with an antagonistic profile at both of these receptors (Kiss et al., 2010). Cariprazine has been shown to occupy both D2 and D3 receptors in the brain of patients with schizophrenia, albeit with a preference for D3 receptors, with ED50 ratios in the threefold to sixfold range (Girgis et al., 2016). This is in contrast to currently available antipsychotic medications, such as clozapine, risperidone and olanzapine, which at antipsychotic-effect dose levels show high occupancy of D2 receptors with no significant occupancy of D3 receptors (Graff-Guerrero et al., 2009; Mizrahi et al., 2011). Therefore, studies have suggested that the superior efficacy of cariprazine against the negative symptoms of schizophrenia (Németh et al., 2017) may arise from its unique pharmacological profile, in particular, its high affinity for D3 receptors compared to other antipsychotics (Gerytán et al., 2011; Kiss et al., 2010). However, the link between the unique pharmacological profile and clinical effectiveness is not yet fully understood because of a lack of pharmacological data at the system level. Investigation of the modulation of gamma oscillations has been considered a useful method to identify molecular mechanisms by which cariprazine influences the symptoms of schizophrenia (Ahnaou, Huysmans, Van de Castelee, & Drinkenburg, 2017; Schulz, Heidmann, et al., 2012).

Gamma oscillations are a measure of synchronized population activity at frequencies between 30 and 90 Hz (Fries, 2009) and are known to be generated by rhythmic firing of fast-spiking parvalbumin-containing perisomatic interneurons (Cardin et al., 2009). The power of gamma oscillations increases during sensory processing, perception, attention, working memory or long-term memory representation in both animals (Lu, Jefferys, Toescu, & Vreugdenhil, 2011) and humans (Herrmann, Munk, & Engel, 2004; Rodriguez et al., 1999), indicating that gamma oscillations are a useful biomarker to investigate cognitive processes at the network level. Abnormal gamma oscillations have been described in several psychiatric diseases, including schizophrenia (Gonzalez-Burgos, Cho, & Lewis, 2015; Uhlhaas & Singer, 2010). In particular, enhanced gamma oscillations have been observed in patients with hallucinations (Baldeweg, Spence, Hirsch, & Gruzelier, 1998) or with more severe positive symptoms (Spencer et al., 2004), whereas reduced gamma oscillations correlate with the negative and cognitive symptom scores of the disease (Cho, Konecky, & Carter, 2006; Lee, Kim, Kim, & Im, 2010).

**What is already known**
- Gamma oscillations are disturbed in patients with schizophrenia and in animal models of the disease.

**What does this study add**
- The novel antipsychotic cariprazine stabilized hippocampal gamma oscillations in rats pretreated with MK-801.

**What is the clinical significance**
- In vitro gamma oscillations are predictive biomarkers to evaluate antipsychotics preclinically at the network level.

NMDA receptor hypofunction has been implicated in the pathophysiology of schizophrenia (Jentsch & Roth, 1999). A single dose of a non-competitive NMDA receptor antagonist, such as ketamine or phencyclidine, induces psychotic, negative and cognitive symptoms in healthy humans resembling those observed in schizophrenia (Newcomer et al., 1999). In addition, patients receiving NMDA antagonists have been reported to experience exacerbations of schizophrenia symptoms (Lahti, Weiler, Tamara Michaelidis, Parwani, & Tamminga, 2001). In rodents, NMDA receptor antagonists induce a schizophrenia-like phenotype, including hyperlocomotion, stereotypes, disruptions in pre-pulse inhibition, impairments in attention, social behaviour and cognitive deficits (Cadinu et al., 2017; Wiescholleck & Manahan-Vaughan, 2013). In these animals, a single acute dose of an NMDA receptor antagonist induced a strong increase in gamma oscillations both in the hippocampus and neocortex (Kehrer et al., 2007; Lemercier, Holman, & Gerevich, 2017). Furthermore, a previous report suggested that a single acute dose of NMDA receptor antagonists mimics acute first-episode schizophrenia, whereas chronic administration simulates the chronic symptoms of the disease with predominating negative symptoms (Jentsch & Roth, 1999).

Previous studies indicated the pivotal modulatory role of D3 receptors in hippocampal gamma oscillations in vitro (Lemercier, Schulz, Heidmann, Kovács, & Gerevich, 2016; Schulz, Heidmann, et al., 2012). With regard to the high preference of cariprazine for D3 receptors, we hypothesized that cariprazine modulates hippocampal gamma oscillatory activity and this effect may underlie its beneficial effects observed in schizophrenia. Therefore, to gain insight on its working mechanism at the network level, we investigated the effects of cariprazine on pharmacologically induced oscillatory activity in hippocampal slices from treatment-naïve and MK-801-treated rats.

### METHODS

#### 2.1 Animals and slice preparation

Acute brain slices were prepared from 6- to 9-week-old (180–230 g) Wistar rats (n = 85) of either sex and own breed in accordance with
the guidelines of the European Union (Directive 2010/63/EU), and
the institutional guidelines were approved by the Berlin Animal Ethics
Committee (Landesamt für Gesundheit und Soziales Berlin,
GO437/12) as previously described (Schulz, Klaft, et al., 2012). The
animals were kept under 12-hr light/dark conditions and given food
and water ad libitum. Animal studies are reported in compliance with
the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman,
2010) and with the recommendations made by the British Journal of
Pharmacology. The animals were anaesthetized with isoflurane
(2.0–2.4 vol%) and then decapitated. MK-801-treated animals
received intraperitoneally a single dose of 5 mg kg⁻¹ MK-801 (diluted
in 1 ml saline/100 g body weight) (Lemercier et al., 2017; Manahan-
Vaughan, von Haebler, Winter, Juckel, & Heinemann, 2008) 24 hr
before slice preparation. Vehicle-treated control animals received
the same amount of saline (0.9% NaCl, 1 ml/100 g). MK-801 induced hy-
erlocomotion and stereotypy, therefore experiments were not blind
to the experimenter. The brains were removed and immediately sub-
merged in an ice-cold sucrose artificial CSF (ACSF) slicing solution
containing 80-mM NaCl, 2.5-mM KCl, 3-mM MgCl₂, 0.5-mM CaCl₂,
25-mM glucose, 85-mM sucrose, 1.25-mM NaH₂PO₄, and 25-mM
NaHCO₃ (320–330 mOsm), enriched with carbogen (95% O₂, 5% CO₂). Further, 400-μm-thick horizontal slices containing the hippo-
campal formation were cut on a vibratome (DSK microslicer DTK-
1294, Dosaka, Japan). The slices were immediately transferred to an
interface-type recording chamber and perfused with a flow rate of
1.7 ml min⁻¹ with warm (36°C) and carbogenated ACSF containing
129-mM NaCl, 3-mM KCl, 21-mM NaHCO₃, 1.25-mM NaH₂PO₄,
1.8-mM MgSO₄, 1.6-mM CaCl₂, and 10-mM glucose. The slices were
allowed to recover for at least 1 hr before starting the experiments.

2.2 | Extracellular recordings

Local field potentials were recorded from the stratum pyramidale in the
CA3b area of the hippocampus with glass pipettes filled with ACSF (resistance <3 MΩ) as described earlier (Çalışkan et al., 2015;
Schulz, Klaft, et al., 2012). Recordings were amplified by a custom-
made amplifier, low-pass filtered at 1 kHz and sampled at 5 kHz by a
CED 1401 interface (Cambridge Electronic Design, Cambridge, UK).

2.3 | Data analysis and statistics

The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and analy-
sis in pharmacology (Curtis et al., 2018). Experiments were designed
to generate groups of equal size. Slices were randomly allocated to
recording chambers and randomized into drug-treated or control
group before treatment. For blinding, operators and analysts were dif-
ferent persons. Group size selection was planned by the program
G*Power3 (Faul, Erdfelder, Lang, & Buchner, 2007). Power spectra
were calculated every 2 min with a 120-s window throughout the
recording. Based on these power spectra, peak power, peak
frequency, half bandwidth, or quality factor (Q factor) of the oscillations
were determined off-line by using a custom-made script for the
Spike2 software (version 7.10, Cambridge Electronic Design, Cam-
bridge, UK). The Q factor of the oscillation (Lemercier et al., 2017)
was calculated by means of the following equation: Q = f₀/B, where f₀
is the peak frequency and B is the bandwidth at 50% of maximum
peak power and was used instead of half bandwidth in experiments
where oscillations desynchronized and altered their peak frequency.
The Q factor describes the relative distribution of the frequencies
around the peak frequency and is therefore independent of changes
in peak frequency. Oscillation parameters show a high variability and
were therefore normalized in every slice to a 10-min baseline period
before drug application, ACh/physostigmine (Physo) wash-out, or
corresponding time in control experiments. Statistical analysis was
performed with GraphPad Prism (GraphPad Software Inc., San Diego,
USA). The D’Agostino–Pearson normality test was used to test the
Gaussian distribution of the data. Absolute power values displayed a
log-normal distribution and are therefore presented as geometric
mean with its confidence interval (CI). All other data are presented as
mean ± SEM. At least four animals were used in each experimental
group. The group data subjected to statistical analysis have a mini-
mum of n = 5 independent samples per group. Several slices of each
brain were used for experiments but not more than one slice per hemisphere for each treatment group. No outliers were removed from
the data. Statistical comparisons between drug-induced effects and
time-matched control changes were performed using Student’s
unpaired t- test. Absolute power values were compared using the
non-parametric Mann–Whitney U test. In all analyses, the significance
level was set at P < .05.

2.4 | Materials

Physostigmine (Physo), MK-801, pramipexole and SB-277011 were
obtained from Tocris Bioscience (Bristol, UK). ACh was purchased
from Sigma-Aldrich (Taufkirchen, Germany) and cariprazine was pro-
vided by Gedeon Richter (Budapest, Hungary). Stock solutions were
prepared in water, and the experimental compounds were further
diluted in ACSF to reach the final concentrations. Cariprazine was
applied at a concentration of 10 μM. Pharmacologically effective car-
iprazine plasma concentrations were 213 and 115 nM in rat and
humans, respectively (Gyertyán et al., 2011; Mauri et al., 2018). Since
brain concentrations were found to be min. 7.6-fold higher than the
corresponding plasma concentrations in rats (Gyertyán et al., 2011),
we estimated a concentration range of 1–2 μM in brain during active
behaviour. To reach this steady-state concentration by diffusion into
the slice held in the interface-type chamber, a factor of 5 was used.

2.5 | Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to
the corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2019/20 (Alexander,
Christopoulos et al., 2019; Alexander, Kelly et al., 2019).

3 | RESULTS

3.1 | D3 receptor activation inhibits hippocampal
gamma oscillations

Bath application of ACh (10 μM) and the acetylcholinesterase inhibitor
physostigmine (2 μM) induced gamma oscillations in the CA3 area of
the hippocampus which reached a plateau after ~90 min with a peak
power of 463.6 μV² (95% CI [183.5, 1171]), peak frequency of
39.1 ± 0.9 Hz and a half bandwidth of 5.6 ± 1.8 Hz (n = 19). The D3
receptor agonist pramipexole (30 μM; Mierau et al., 1995) significantly
decreased the peak power of these oscillations to 38.1 ± 8.2% (P = .002; Figure 1a,b,c) and broadened the half bandwidth to
198.1 ± 19.1% (P = .002), whereas it did not significantly affect the
peak frequency of the gamma oscillations.

The dopamine D3 receptor antagonist SB-277011 (30 μM) did
not affect the power, peak frequency or half bandwidth compared to
control gamma oscillations in the hippocampus (Figure 1d,e).

3.2 | Cariprazine increases the periodicity of non-
saturated hippocampal gamma oscillations

Next, we investigated the effect of cariprazine on hippocampal gamma
oscillations. Cariprazine (10 μM), similar to the D3 receptor antagonist
SB-277011, did not change any oscillation parameters when the oscil-
lations were induced by saturating concentrations of ACh (10 μM) and
physostigmine (2 μM; peak power: 134.9 ± 14.7%, n = 12,
vs. 157.8 ± 33.1% with control, n = 7, P = .477; peak frequency:
98.2 ± 1.9% vs. 99.2 ± 1.1% with control, P = .720; half bandwidth:
109.1 ± 8.7% vs. 96.3 ± 6.6% with control, P = .321; data not shown).
To test whether non-saturated gamma oscillations were differentially
affected by cariprazine, we induced oscillations with lower concentrations of ACh (5 μM) and physostigmine (1 μM, Figure 2). These oscillations developed with a significantly lower peak power (43.7 μV², 95% CI: 19.2 to 99.1, n = 19, P = .015) and a higher peak frequency (45.9 ± 1.1 Hz, P < .001), while the half bandwidth remained unchanged (5.9 ± 0.6 Hz), consistent with previous observations with carbachol-induced oscillations (Fisahn, Pike, Buhl, & Paulsen, 1998).

Similar to the saturated gamma oscillations, cariprazine (10 μM) did not significantly modulate the power and peak frequency of these oscillations (Figure 2d,e,f) compared to the changes with control during the same time interval. However, the half bandwidth of the non-saturated oscillations was significantly reduced to 90.7 ± 5.9% (P = .044 compared to the control change: 113.4 ± 8.2%, Figure 2d,g).

3.3 | Cariprazine shows a partial agonistic profile when modulating gamma oscillations

To evaluate how cariprazine interacts with the D3 receptor to modulate gamma oscillations depending on the current level of D3 receptor activation, we applied cariprazine prior to pramipexole treatment that was administered at two different concentrations. The low concentration of pramipexole (10 μM) did not significantly decrease the oscillation power, although a slight and non-significant reduction was observed (Figure 3a,c). Cariprazine, however, potentiated the effect of 10-μM pramipexole (Figure 3a,c).

On the contrary, the higher concentration of pramipexole (30 μM) decreased the power (P = .011) and increased the half bandwidth (P = .003), as well as the peak frequency (P < .001; Figure 3b-e). Cariprazine (10 μM) inhibited the effect of pramipexole on the peak power (P = .048) and peak frequency (P = .016) whereas the effect on the half bandwidth was not significant (Figure 3b-e). Thus, while cariprazine augmented the effect of the agonist at low D3 receptor stimulation, it had an antagonistic effect when the agonist tone was high.

3.4 | Cariprazine does not affect the temporal dynamics of hippocampal gamma oscillations in non-treated animals

Neural network activity is dynamic and characterized by the appearance and disappearance of synchronization in time. Therefore, we

FIGURE 2 Cariprazine increases the periodicity of non-saturated hippocampal gamma oscillations. (a-b) Spectrograms show gamma oscillations in the CA3 area induced by non-saturating concentrations of ACh (5 μM) and Physio (1 μM) without (a) and with cariprazine (10 μM) application (b). Brighter colours mean higher power values. (c) Original traces (top) and power spectra (below) of induced gamma oscillations in control slices after gamma oscillation induction (baseline) and 60 min later (control). (d) Original traces (top) and power spectra (below) of induced gamma oscillations before (baseline) and after cariprazine (10 μM) application. The inset shows the same power spectra rescaled to demonstrate the effect of cariprazine on the half bandwidth. (e-g) Bar diagrams show the effect of cariprazine (n = 7) on peak power (e), peak frequency (f) and peak bandwidth (g) compared to time-matched parameters from control slices (n = 7). CAR, cariprazine; Cont., control; Freq., frequency; Norm, normalized; Physio, physostigmine; PSD, power spectral density. Data are presented as mean ± SEM.* P < .05
investigated whether cariprazine was capable of modulating gamma activity in the temporal domain. We induced gamma oscillations in the hippocampus, followed by interruption of the ACh/physostigmine application for 40 min after 100 min of perfusion. Following wash-out of ACh/physostigmine, the gamma oscillations desynchronized, as observed by a significant decrease in the power to 6.6 ± 2.1% (Figure 4a,d), while the peak frequency increased by 15.9 ± 4.4% (Figure 4b). Because of this shift in frequency, we expressed the spectral bandwidth as the \( Q \) factor expressing the relative distribution of the frequencies around the particular peak frequency, as described in Section 2. The \( Q \) factor significantly decreased during the wash-out of ACh/physostigmine to 27.1 ± 0.64 Hz, \( P = .033 \) (Figure 4c). After repeated wash-in, gamma oscillations resynchronized: The power increased again to 69.2 ± 6.9% of the baseline, 30 min after repeated wash-in, and the \( Q \) factor increased to 59.2 ± 9.6%, while the \( Q \) factor increased to 74.3 ± 11.8% (Figure 4c) and the peak frequency decreased to 103.8 ± 1.4% (Figure 4b).

### 3.5 Cariprazine stabilizes hippocampal gamma oscillations in MK-801-treated rats

In the next series of experiments, we investigated whether cariprazine affects disturbed gamma oscillations. To accomplish this, the effects of cariprazine were studied in hippocampal slices of rats that received a single dose of MK-801, a model of first-episode schizophrenia (Manahan-Vaughan et al., 2008; Wiescholleck & Manahan-Vaughan, 2013). In line with previous results (Lemercier et al., 2017), the hippocampal gamma oscillations induced by bath application of ACh (10 \( \mu \)M) and physostigmine (2 \( \mu \)M) had a significantly higher peak power after 90 min of induction compared to saline-treated animals (\( P < .001 \) Figure 5a,b,d) and a broader half bandwidth (MK-801: 5.19 ± 0.64 Hz, \( P = .033 \), compared to saline-treated animals: 3.55 ± 0.37 Hz; not shown); however, the \( Q \) factor of the oscillations did not change (MK-801: 9.9 ± 1.0, \( P = .103 \), compared to saline...
treatment: 12.5 ± 1.2; not shown). Similarly, the peak frequency of the oscillations was not significantly altered (MK-801: 35.1 ± 1.1 Hz, \( P = .196 \), compared to saline-treated animals: 33.3 ± 0.7 Hz, not shown). MK-801 treatment affected the temporal dynamics of the oscillatory activity. The power of the oscillations did not stabilize after approximately 90 min but continuously increased to 208.1 ± 26.7% after 160 min of induction which is a clear difference compared to saline-treated control animals where the power remained stable (103.3 ± 7.8%, \( P < .001 \), Figure 5e,f). Cariprazine (10 \( \mu \)M) applied for 60 min after 100-min induction in MK-801-treated animals prevented the continuous increase in the power compared to the MK-801 control change (128.6 ± 12.6%, \( P = .010 \), Figure 5e,f). In contrast, the bandwidth and frequency of the oscillations remained constant during this time interval and cariprazine did not significantly change any of the parameters (Figure 5f).

### 3.6 Cariprazine accelerates the temporal dynamics of gamma oscillations in the hippocampus of MK-801-treated animals

Wash-out of ACh/physostigmine gradually desynchronized gamma oscillations in MK-801-treated rats (Figure a-d). The power of the oscillations decreased to 8.5 ± 1.1% after 40 min. During the same time, peak frequency showed a non-significant trend to increase and the Q factor significantly decreased to 34.5 ± 2.7% (Figure 6c). Repeated wash-in of ACh and physostigmine resynchronized gamma oscillations by increasing the power to 65.8 ± 11.9% and the Q factor to 66.5 ± 6.1% (Figure 6a,c). The peak frequency further increased to 109.1 ± 1.9% of the baseline (Figure 6b,g). Cariprazine did not influence the dynamics of the peak power (Figure 6a,f). The oscillations achieved in the presence of cariprazine 30 min after re-application of ACh/physostigmine 69.9 ± 15.8% of their initial power. Similarly, the peak frequency further increased and was comparable to the changes with control (Figure 6b,g). However, cariprazine clearly and significantly accelerated the increase in Q factor after repeated administration of ACh/physostigmine reaching 97.9 ± 4.8% of the original baseline (\( P = .006 \), Figure 6c,h), thereby increasing the quality of oscillations during the resynchronization period.

### 4 DISCUSSION

The main findings of the present study are that the novel antipsychotic cariprazine, (a) does not modulate strong gamma oscillations but slightly improves the periodicity of moderate and unsaturated gamma activity, (b) behaves as a partial agonist at the network level when challenged with the \( D_3 \) receptor agonist pramipexol,
(c) stabilizes the power of gamma oscillations in MK-801-treated rats and (d) accelerates the resynchronization of gamma oscillations in MK-801-treated animals.

The present results derived from application of pramipexole alone demonstrate that stimulation of D₃ receptors consistently decreases gamma activity in the hippocampus. These data are in line with our previous observations from other agonists showing that activation of D₃ receptors decreases the power of gamma oscillations and selective D₃ receptor antagonists prevent this effect (Lemercier et al., 2016; Schulz, Heidmann, et al., 2012). In slices from healthy brains, cariprazine only affected weak gamma oscillations induced by lower and non-saturating concentrations of ACh by reducing the half bandwidth of these oscillations. There were no significant effects on strong and saturated gamma oscillations. These results suggest that cariprazine increases the synchronization of not fully developed oscillations by improving their periodicity towards the dominating frequency. The increased synchronization might support communication between cells and cell assemblies.

To investigate the D₃ receptor partial agonist property of cariprazine, we modelled pharmacologically different D₃ receptor tones by applying pramipexole at moderate (10 μM [low D₃ receptor tone]) or high (30 μM [high D₃ receptor tone]) concentrations and applied cariprazine under these conditions. Such an experimental paradigm might be considered a model of endogenous "selective" D₃ receptor activation. In these pramipexole challenge experiments, we confirmed that cariprazine behaves as a D₃ receptor partial agonist, namely under low D₃ receptor tone cariprazine acts predominantly as a D₃ receptor agonist, enhancing D₃ receptor activation and decreasing gamma oscillations. On the contrary, under high D₃ receptor tone cariprazine behaves as a D₃ receptor antagonist and attenuates the inhibitory effects of high D₃ receptor activation on gamma oscillations. Direct enhancement or reduction of gamma oscillations under control conditions could be counterproductive because they may lead to psychiatric symptoms, as shown in studies in patients with various psychiatric diseases and corresponding gamma oscillation alterations (Dickinson, Bruyns-Haylett, Jones, & Milne, 2015; Herrmann & Demiralp, 2005; Uhlaas & Singer, 2015). Our understanding of the function and role of dopamine D₃ receptors in schizophrenia pathophysiology is rather limited. D₃ receptors have a high affinity for dopamine (Sokoloff, Giros, Martres, Bouthenet, & Schwartz, 1990) and are suggested to be activated by volume transmission during the slower tonic dopamine release from dopaminergic fibres (Grace, 2016), and control the amplitude of the fast, phasic dopamine release during behaviourally salient stimuli (Sokoloff and Le Foll, 2017). In schizophrenia, this fine control of the phasic dopamine release amplitude is disturbed, resulting in a state of aberrant salience (Kapur,
Our findings suggest beneficial effects of the partial agonistic characteristic of cariprazine via normalization of the disturbed gamma oscillations by stabilizing the dopamine effects in the hippocampus. The normalizing effect of cariprazine at the level of neural networks, which was apparent at stable oscillations, could also be observed in pathological hippocampal networks. MK-801 is considered as one of the most reliable models to induce a disease-like phenotype in animals, including the negative and cognitive symptoms of schizophrenia (Cadinu et al., 2017; Meltzer et al., 2013). Hippocampal gamma oscillations in these animal models were found to be abnormally increased both in vivo (Kittelberger, Hur, Sazegar, Keshavan, & Kocsis, 2012) and in vitro (Kehrer et al., 2007; Lemercier et al., 2017). These electrophysiological abnormalities of gamma oscillations were suggested to underlie the symptoms of the disease (Gonzalez-Burgos et al., 2015; Uhlhaas & Singer, 2010) and have been shown to be modulated by at least some of the available antipsychotics (Hudson, Rind, O’Brien, & Jones, 2016; Schulz, Heidmann, et al., 2012). In our in vitro experiments, following MK-801 pretreatment, the oscillations did not reach a plateau and continuously increased until the end of the measurement. Application of cariprazine, acting as a partial agonist at the D3 receptors, effectively stabilized the unbridled oscillations and prevented the network from the deleterious effects of MK-801 pretreatment (Figure 5c). This balancing activity could be one important mechanism by which cariprazine reaches its beneficial behavioural effects during positive and negative symptoms.

The temporal dynamics of gamma oscillatory activity in slices can be considered a plastic capability of the network. The second induction of gamma oscillations in the same network occurs significantly faster indicating that plastic changes had happened during the first induction and the circuitry remembers earlier oscillations (Zarnadze et al., 2016). This paradigm might be a physiological model of synaptic plasticity at the network level rather than selective electrical stimulation of one of the inputs at a chosen frequency. The speed of the resynchronization of gamma oscillations thus indicates the extent of activity-dependent network modification in the hippocampus within a given time. Acceleration of this resynchronization may therefore indicate a dynamic network reorganization, which may be of benefit to cognitive functions (Reinhart & Woodman, 2014). In earlier observations, antagonism at D3 receptors was found to speed up the second synchronization (Lemercier et al., 2016), suggesting that D3 receptors have negative effects on neuronal plasticity at the network level and antagonism at these receptors may support plasticity within the network. These data may provide one possible explanation as to why D3 receptor knockout animals perform better in cognitive tests and why...
D3 receptor antagonists have pro-cognitive effects in animal models (Nakajima et al., 2013). The partial agonist cariprazine did not alter the dynamics in control animals but significantly accelerated the resynchronization in MK-801-treated animals as measured by means of the Q factor. The Q factor (as described in Section 2) describes the distribution of the frequencies around the peak and herewith the periodicity of the oscillations (Lemercier et al., 2017). After wash-out of ACh, the gamma oscillations desynchronized, as evident from the decreasing power and Q factor values. The resynchronization occurred significantly faster in the presence of cariprazine but only in MK-801-treated rats. Thus, these results suggest that cariprazine may have no effect on cognitive functions in healthy animals but could improve cognitive symptoms in schizophrenia models. In line with this, cariprazine has been shown to be effective against these domains in animal models (Barnes et al., 2018; Neill et al., 2016; Watson et al., 2016; Zimnisky et al., 2013) and in patients with schizophrenia (Daniel et al., 2017).

D3 receptors are expressed in the rat and human cortex (Bouthenet et al., 1991; Khan et al., 1998; Richtand, Kelsoe, Segal, & Kuczenski, 1995). In the hippocampus, the expression of the D3 receptor mRNA was found in the pyramidal cell layer of the cornu ammonis (Bouthenet et al., 1991) and the receptor protein on dendrites in both the stratum oriens and radiatum (Khan et al., 1998), suggesting the presence of D3 receptors on pyramidal cell dendrites. Although the expression of the dopamine D3 receptor is low in these regions, it seems comparable to that of D2 receptors (Khan et al., 1998). Additionally, the D3 receptor has the highest affinity for dopamine amongst all dopamine receptor subtypes, particularly when it is uncoupled from G proteins (Sokoloff et al., 1990; Van Tol et al., 1991). There are several possible cellular mechanisms by which D3 receptors on pyramidal cells can modulate local neuronal oscillations. In prefrontal pyramidal cells and auditory brainstem interneurons, D3 receptor activation was shown to decrease the excitability by inhibition of calcium influx via low-voltage-activated Cav3.2 calcium channels localized to the axon initial segment (Bender, Ford, & Trussell, 2010; Clarkson, Liptak, Gee, Sohal, & Bender, 2017). D3 receptors were also found to reduce inhibitory synaptic inputs in CA1 pyramidal cells by inducing endocytosis of GABA_A receptors (Swant, Stramiello, & Wagner, 2008). Since synchronous perisomatic inhibition by fast-spiking interneurons is thought to be responsible for the generation of the gamma oscillations, reduction of the synchronizing currents by D3 receptors could explain the gamma-inhibiting effects of these receptors.

Although our experiments with the D3 receptor agonist pramipexole and cariprazine indicated that cariprazine modulates gamma oscillations by acting on D3 receptors, antipsychotics often display a wide pharmacological profile with effective interactions on multiple receptors. In case of cariprazine, it has been reported that it possesses also partial agonistic and antagonistic actions at 5-HT1A, 5-HT2A and 5-HT2B receptors, respectively (Kiss et al., 2010). Among them, the 5-HT1A receptors (Krause & Jia, 2005) were found to modulate gamma oscillations in the hippocampus suggesting that besides the D3 receptors, these receptors might also be involved in the mechanisms of action of cariprazine. Further investigations are needed to fully characterize the contribution of other receptors targeted by cariprazine in the modulation of gamma oscillations.

In summary, our results showed a dopamine D3 receptor partial agonistic profile for cariprazine at the network level by studying oscillatory activities. Additionally, cariprazine had a clear stabilizing effect on pathological hippocampal gamma oscillations in an NMDA hypofunction model of schizophrenia, which can be explained by its partial agonistic profile. Considering that perturbations in gamma oscillations have been suggested to be relevant to the positive, negative, and cognitive symptoms of schizophrenia, the ability of cariprazine to normalize gamma oscillations in the acute MK-801 model of schizophrenia might further explain the clinical effectiveness of this novel agent. Additional experiments in the future are warranted to investigate the effects of cariprazine in the chronic MK-801 model. The presented findings demonstrate the predictive validity of in vitro gamma oscillations as biomarkers to study the effects of antipsychotics preclinically at the network level.

ACKNOWLEDGEMENTS
We thank Katrin Schulze for the assistance with the MK-801-treated rats and Luisa A. Hasam-Henderson for her support in electrophysiological measurements. Editorial support was provided by Cactus Communications (Mumbai, India) and Cherisse Loucks, PhD of Allergan (Madison, New Jersey, USA).

AUTHOR CONTRIBUTIONS
M.A.M., C.E.L. and C.K. performed the experiments and analysed the data. B.K., B.L. and N.A. actively contributed to designing the experiments and interpretation of data. Z.G. designed the experiments and analysed and interpreted the data. All authors drafted the manuscript.

CONFLICT OF INTEREST
The study was supported by a grant from Allergan Plc and Gedeon Richter Plc. Allergan Plc and Gedeon Richter Plc were involved in the study design, analysis, interpretation of data, the decision to present results, and writing of manuscript. Charité – Universitätsmedizin Berlin was involved in the study design, all experimental parts, report and discussion of the results, and writing the manuscript. B.L. and B.K. are full-time employees at Gedeon Richter Plc. N.A. is a full-time employee at Allergan. M.A.M., C.E.L., C.K. and Z.G. are affiliated at Charité – Universitätsmedizin Berlin.

DECLARATION OF TRANSPARENCY AND SCIENTIFIC RIGOUR
This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research as stated in the BJP guidelines for Design & Analysis, and Animal Experimentation and as recommended by funding agencies, publishers and other organisations engaged with supporting research.
REFERENCES

Ahnaou, A., Huysmans, H., Van de Casteele, T., & Drinkenburg, W. H. I. M. (2017). Cortical high gamma network oscillations and connectivity: A translational index for antipsychotics to normalize aberrant neuronal physiological activity. *Translational Psychiatry*, 7(12), 1285. https://doi.org/10.1038/s41398-017-0002-9

Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peter, J. A., ... CGTP Collaborators (2019). The concise guide to pharmacology 2019/2020: G protein-coupled receptors. *British Journal of Pharmacology*, 176, S1–S141. https://doi.org/10.1111/bjp.14748

Alexander, S. P. H., Keely, E. A., Mathie, A., Peter, J. A., Veale, E. L., Armstrong, J. H., ... GTP collaborators (2019). The concise guide to pharmacology 2019/2020: Introduction and other protein target. *British Journal of Pharmacology*, 176, S1–S50. https://doi.org/10.1111/bjp.14747

Baldegger, T., Spence, S., Hirsch, S. R., & Gruzelier, J. (1998). Gamma-band electroencephalographic oscillations in a patient with somatic hallucinations. *Lancet*, 352(9128), 620–621. https://doi.org/10.1016/S0140-6736(05)79575-1

Barnes, S. A., Young, J. W., Markou, A., Adham, N., Gyertyán, I., & Kiss, B. (2018). The effects of cariprazine and aripiprazole on PCP-induced deficits on attention assessed in the 5-choice serial reaction time task. *Psychopharmacology*, 235(5), 1403–1414. https://doi.org/10.1007/s00213-018-4857-0

Bender, K. J., Ford, C. P., & Trussell, L. O. (2010). Dopaminergic modulation of axon initial segment calcium channels regulates action potential initiation. *Neuron*, 68(3), 500–511. https://doi.org/10.1016/j.neuron.2010.09.026

Birnbaum, R., & Weinberger, D. R. (2017). Genetic insights into the neuropsychiatric disorders by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C](+)-PHNO. *Psychopharmacology*, 233(19–20), 3503–3512. https://doi.org/10.1007/s00213-016-4382-y

Brodie, A. J. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C](+)-PHNO. *Psychopharmacology*, 233(19–20), 3503–3512. https://doi.org/10.1007/s00213-016-4382-y

Cardin, J. A., Carlén, M., Meletis, K., Knoblich, U., Zhang, F., Deisseroth, K., ... Moore, C. I. (2009). Driving fast-spiking cells induces gamma rhythm and controls sensory responses. *Nature*, 459(7247), 663–667. https://doi.org/10.1038/nature08002

Cho, R. Y., Konecky, R. O., & Carter, C. S. (2006). Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. *Proceedings of the National Academy of Sciences of the United States of America*, 103(52), 19878–19883. https://doi.org/10.1073/pnas.0609440103

Clarkson, R. L., Liptak, A. T., Gee, S. M., Sohal, V. S., & Bender, K. J. (2017). D3 receptors regulate excitability in a unique class of prefrontal pyramidal cells. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 37(24), 5846–5860. https://doi.org/10.1523/JNEUROSCI.0310-17.2017

Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Gembycz, M. A., ... Ahluwalia, A. (2018). Experimental design and analysis and their reporting II: Updated and simplified guidance for authors and peer reviewers. *British Journal of Pharmacology*, 175(7), 987–993. https://doi.org/10.1111/bjp.14153

Daniel, D., Nasrallah, H., Earley, W., Durgam, S., Lu, K., Szatmári, B., ... Patel, M. (2017). Effects of cariprazine on negative symptoms, cognitive impairment, and prosocial functioning in patients with predominant negative symptoms: Post hoc analysis of a phase III, placebo-, and active-controlled study. *Schizophrenia Bulletin*, 43(Suppl 1), S13. https://doi.org/10.1093/schbul/sbx021.036

Dickinson, A., Bryns-Haylett, M., Jones, M., & Milne, E. (2015). Increased peak frequency in individuals with higher levels of autistic traits. *The European Journal of Neuroscience*, 41(8), 1095–1101. https://doi.org/10.1111/ejn.12881

Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible and powerful statistical analysis program for the social, behavioral, and biomedical sciences. *Behavior Research Methods*, 39(2), 175–191. https://doi.org/10.3758/bf03193146

Fisahn, A., Pike, F. G., Buhl, E. H., & Paulsen, O. (1998). Cholinergic induction of network oscillations at 40 Hz in the hippocampus in vitro. *Nature*, 394(6689), 186–189. https://doi.org/10.1038/28179

Fries, P. (2009). Neuronal gamma-band synchronization as a fundamental process in cortical computation. Annual Review of Neuroscience, 32, 209–224. https://doi.org/10.1146/annurev.neuro.051508.135603

Girgis, R. R., Silfstein, M., D’Souza, D., Lee, Y., Pericollu, A., Ghahramani, P., ... Rakhit, A. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. *Psychopharmacology*, 233(19–20), 3503–3512. https://doi.org/10.1007/s00213-016-4382-y

Gonzalez-Burgos, G., Cho, R. Y., & Lewis, D. A. (2015). Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. *Biological Psychiatry*, 77(12), 1031–1040. https://doi.org/10.1016/j.biopsych.2015.03.010

Grace, A. A. (2016). Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. *Nature Reviews. Neuroscience*, 17(8), 524–532. https://doi.org/10.1038/nrn.2016.57

Graff-Guerrero, A., Mamo, D., Shammi, C. M., Mizrahi, R., Marcon, H., Barsoum, P., ... Kapur, S. (2009). The effect of antipsychotics on the high-affinity state of D3 and D2 receptors: A positron emission tomography study with [11C](+)-PHNO. *Archives of General Psychiatry*, 66(6), 606–615. https://doi.org/10.1001/archgenpsychiatry.2009.43

Gyertyán, I., Kiss, B., Ságky, H., Laszy, J., Szabó, G., Szabados, T., ... Szombathelyi, Z. (2011). Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D2 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. *Neurochemistry International*, 59(6), 925–935. https://doi.org/10.1016/j.neuint.2011.07.002

Harding, S. D., Sharma, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S., ... NC-IUPHAR (2018). The IUPHAR/BPS guide to pharmacology in 2018: Updates and expansion to encompass the new guide to pharmacology in 2019/2020: Introduction and other protein target. *Biomedical Sciences*, 41(8), 135603. https://doi.org/10.1038/s41560-018-0549-4

Herrmann, C. S., & Demiralp, T. (2005). Human EEG gamma oscillations in neuropsychiatric disorders. *Clinical Neurophysiology*, 116(12), 2719–2733. https://doi.org/10.1016/j.clinph.2005.07.007
synchronization of human brain activity. Nature, 397(6718), 430–433. https://doi.org/10.1038/17120

Schulz, S. B., Heidmann, K. E., Mike, A., Klaft, Z. J., Heinemann, U., & Gerevich, Z. (2012). First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D₃ receptors. British Journal of Pharmacology, 167(7), 1480–1491. https://doi.org/10.1111/j.1476-5381.2012.02107.x

Schulz, S. B., Klaft, Z. J., Rösler, A. R., Heinemann, U., & Gerevich, Z. (2012). Purinergic P2X, P2Y and adenosine receptors differentially modulate hippocampal gamma oscillations. Neuropharmacology, 62(2), 914–924. https://doi.org/10.1016/j.neuropharm.2011.09.024

Sokoloff, P., Giros, B., Martres, M. P., Bouthenet, M. L., & Schwartz, J. C. (1990). Molecular cloning and characterization of a novel dopamine receptor (D₃) as a target for neuroleptics. Nature, 347(6289), 146–151. https://doi.org/10.1038/347146a0

Sokoloff, P., & Le Foll, B. (2017). The dopamine D₃ receptor, a quarter century later. The European Journal of Neuroscience, 45(1), 2–19. https://doi.org/10.1111/ejn.13390

Spencer, K. M., Nestor, P. G., Perlmutter, R., Niznikiewicz, M. A., Klump, M. C., Frumin, M., ... McCarley, R. W. (2004). Neural synchrony indexes disordered perception and cognition in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 101(49), 17288–17293. https://doi.org/10.1073/pnas.0406074101

Swant, J., Stramiello, M., & Wagner, J. J. (2008). Postsynaptic dopamine D₃ receptor modulation of evoked IPSCs via GABA_A receptor endocytosis in rat hippocampus. Hippocampus, 18(5), 492–502. https://doi.org/10.1002/hipo.20408

Uhlhaas, P. J., & Singer, W. (2010). Abnormal neural oscillations and synchrony in schizophrenia. Nature Reviews. Neuroscience, 11(2), 100–113. https://doi.org/10.1038/nrn2774

Uhlhaas, P. J., & Singer, W. (2015). Oscillations and neuronal dynamics in schizophrenia: The search for basic symptoms and translational opportunities. Biological Psychiatry, 77(12), 1001–1009. https://doi.org/10.1016/j.biopsych.2014.11.019

Van Tol, H. H., Bunzow, J. R., Guan, H. C., Sunahara, R. K., Seeman, P., Niznik, H. B., & Civelli, O. (1991). Cloning of the gene for a human dopamine D₄ receptor with high affinity for the antipsychotic clozapine. Nature, 350(6319), 610–614. https://doi.org/10.1038/350610a0

Watson, D. J. G., King, M. V., Gyertyán, I., Kiss, B., Adham, N., & Fone, K. C. F. (2016). The dopamine D₁/D₅-preferring D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. European Neuropsychopharmacology, 26(2), 208–224. https://doi.org/10.1016/j.euroneuro.2015.12.020

Wiescholleck, V., & Manahan-Vaughan, D. (2013). Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis. Neuropharmacology, 74, 48–58. https://doi.org/10.1016/j.neuropharm.2013.01.001

Zarnadze, S., Bäuerle, P., Santos-Torres, J., Böhm, C., Schmitz, D., Geiger, J. R., ... Gloveli, T. (2016). Cell-specific synaptic plasticity induced by network oscillations. eLife, 5, e14912. https://doi.org/10.7554/eLife.14912

Zimnisky, R., Chang, G., Gyertyán, I., Kiss, B., Adham, N., & Schmauss, C. (2013). Cariprazine, a dopamine D₃-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology, 226(1), 91–100. https://doi.org/10.1007/s00213-012-2896-5

How to cite this article: Meier MA, Lemercier CE, Kulisch C, et al. The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices. Br J Pharmacol. 2020; 177:1622–1634. https://doi.org/10.1111/bph.14923